Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) – Pipeline Review, H1 2018’, provides in depth analysis on Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Infectious Disease, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Respiratory, Genetic Disorders and Other Diseases under development targeting Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

– The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects

– The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Chugai Pharmaceutical Co Ltd

InflaRx NV

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Overview

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Chugai Pharmaceutical Co Ltd

InflaRx NV

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Drug Profiles

AcPepA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bikaciomab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cemdisiran Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin LA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-2 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mubodina Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-19 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-20 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-21 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit Complement C5 for Immunology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101295 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101348 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab next generation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3918 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6107 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-005 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Coversin Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Dormant Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Discontinued Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

Feb 12, 2018: Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

Jan 16, 2018: Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment

Dec 26, 2017: Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)

Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients

Dec 11, 2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting

Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint

Dec 04, 2017: Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

Nov 06, 2017: Alexion Receives New Japanese Patent for Soliris (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio

Nov 01, 2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting

Oct 23, 2017: FDA Approves Soliris (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Akari Therapeutics Plc, H1 2018

Pipeline by Alexion Pharmaceuticals Inc, H1 2018

Pipeline by Alnylam Pharmaceuticals Inc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Pipeline by InflaRx NV, H1 2018

Pipeline by ISU ABXIS Co Ltd, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by NovelMed Therapeutics Inc, H1 2018

Pipeline by Noxxon Pharma AG, H1 2018

Pipeline by Ophthotech Corp, H1 2018

Pipeline by Ra Pharmaceuticals Inc, H1 2018

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Pipeline by Swedish Orphan Biovitrum AB, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports